Irinotecan
Fallopian Tube Neoplasms
Eli Lilly and CompanySmall moleculePhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 63/ 100
- Competitive Position
- 89/ 100
Competitive context
24 Active assets in the Fallopian Tube Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(+)-VINCRISTINE Eli Lilly and Company | Phase 4 | BBB |
Carboplatin Eli Lilly and Company | Phase 3 | BB |
Inno-206 Eli Lilly and Company | Phase 3 | BB |
Cyclophosphamide Seagen, a wholly owned subsidiary of Pfizer | Phase 3 | B |
Hycamtin Eli Lilly and Company | Phase 3 | B |
View all 49 →
Same molecule, other indications
Irinotecan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →